HemoSonics

HemoSonics is a private, commercial-stage diagnostics company focused on revolutionizing bleeding management through its proprietary Quantra® System. The platform utilizes a patented ultrasound-based technology called SEER Sonorheometry to deliver rapid, accurate viscoelastic test results at the point-of-care or in the lab. The company targets high-acuity hospital settings where timely hemostasis assessment is critical, with a clear value proposition in reducing transfusion volumes, hospital length of stay, and overall care costs. HemoSonics has achieved significant regulatory milestones, including FDA clearance for use in peripartum obstetric procedures.

SEER (Sonic Estimation of Elasticity via Resonance) Sonorheometry: An ultrasound-based, cartridge-based viscoelastic testing system that measures clot stiffness via induced resonance without mechanical clot contact.

HemoSonics competes directly with established viscoelastic testing leaders Haemonetics (TEG) and Werfen/Instrumentation Laboratory (ROTEM). Its primary competitive differentiation is the SEER technology, which offers a closed cartridge system, robustness to vibration, and no mechanical clot disruption. The market is also served by conventional plasma-based coagulation tests, against which VET competes for clinical utility in dynamic settings.